glp-1 therapies How to use receptor agonist therapy safely and effectively GLP-1 Therapies and Dermatology: A

Preserving and rebuilding lean muscle is one of the most important predictors of long-term metabolic health

Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit

[ SOURCE: Reuters] As of June 2, 2025, the JPML reports there are 1,882 cases pending in the MDL -3094 IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation

There are various recommendations on when these drugs should be stopped in the perioperative period

But the triple mechanism intensifies some of these effects compared to what semaglutide and tirzepatide side effects look like individually

34 However, Elkind-Hirsch et al